BioSpace News Archive

Vaxart, Inc. (NASDAQ: VXRT) said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.

Marrone Bio Innovations, Inc. (NASDAQ: MBII), has acquired exclusive rights to high-performing strains of Streptomyces acidiscabies , allowing for the accelerated commercialization of a new, second-generation bioherbicide, MBI-006.

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus Medical Technologies (Cyrus), and Express Medical Solutions LLC. (Medexsol) to serve as the exclusive distributors of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Cyprus, the United Arab Emirates and Oman, and Saudi Arabia and Bahrain, respectively.

Corcept Therapeutics Incorporated today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share.

UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE MOBILE 2 study, which is evaluating the efficacy and safety of bimekizumab in adults with active ankylosing spondylitis.

Hyperfine, Inc., the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, and the Brain Tumor Foundation have launched a new partnership to provide access to free brain scans across the United States.

Better Health Publishing—A landmark multi-center phase II clinical trial just published in Nutrients, shows that researched dietary supplement, modified citrus pectin (P-MCP), provides benefits for biochemically relapsed prostate cancer (BRPC) patients

Neogene Therapeutics, Inc. today announced the appointment of Raphaël Rousseau, M.D., Ph.D. as Chief Medical Officer.

Debiopharm, a Swiss biopharmaceutical company, announced the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors.

Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.